[Click eStock] "Keeps Pharma Accelerates Pharmaceutical and Biotech-Focused Growth... New Drug Value Set to Expand"

According to recent evaluations, Keeps Pharma is accelerating its transition towards a pharmaceutical and biotech-focused business structure, led by targeted anti-cancer drugs and an oral peptide platform. As clinical development of its core pipelines progresses smoothly and related business sales grow rapidly, the company is expected to demonstrate strong mid- to long-term growth potential.

According to the Korea IR Council’s Technology Analysis Report on July 24, Keeps Pharma is strengthening its new drug development competitiveness, focusing on the FRα (Folate Receptor Alpha)-targeted anti-cancer agent "Idetrexed" and the oral peptide drug delivery platform "Oraloid™".

The report explains that since Keeps Pharma entered the pharmaceutical and biotech business in 2020, it restructured its business into a pharmaceutical and biotech company mainly specializing in the manufacturing and sales of prescription medicines by merging Korea Global Pharm in 2025. As new drug research and development outcomes become increasingly visible, the report notes that its mid- to long-term growth momentum is also strengthening.

In particular, the clinical development results for Idetrexed, the company’s core pipeline, were analyzed positively. Idetrexed confirmed both anti-cancer activity and safety in Phase 1 clinical trials. Currently, Phase 1b/2a trials are underway in Europe in combination with AstraZeneca's PARP inhibitor Lynparza (Olaparib). Furthermore, domestic approval for a Phase 2 trial plan (IND) targeting ovarian cancer is also pending.

Kim Myoungsun, Senior Researcher at the Korea IR Council, stated, "Keeps Pharma is promoting commercialization of its core new drug pipelines based on a stable business foundation," and added, "Through a strategy focused on pharmaceutical and biotech growth, the company is expected to continuously enhance its corporate value in the mid- to long-term."

The report also positively assessed its earnings growth. On a consolidated basis, sales increased from 92.1 billion won in 2023 to 170.2 billion won in 2025. Over the same period, sales from the pharmaceutical and biotech division surged from 6.4 billion won to 49.2 billion won. As a result, the share of pharmaceutical and biotech business in total sales expanded to 28.9%, according to the report.

The report also highlighted the high possibility of further business performance improvement in the future. It anticipated improved profitability, explaining that Keeps Pharma has secured multiple cash-generating sources by operating both anti-cancer pharmaceutical and drug distribution businesses in parallel.

This report concludes that Keeps Pharma is strengthening its foundation for mid- to long-term growth, based on clinical advancements in its core new drug pipelines and expanding pharmaceutical and biotech sales.

This content was produced with the assistance of AI translation services.